



EANM DETECT Abstract Published and Presentation Details

London, UK, 8 October 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been published ahead of the upcoming congress of the European Association of Nuclear Medicine (EANM). The annual congress is taking place from 19-23 October 2024 in Hamburg, Germany.

The abstract titled “**Visualisation of Superficial Peritoneal Endometriosis with ^{99m}Tc-maraciclalide**” is available in the EANM ’24 Abstract book [here](#) (until 7 November 2024) and on our website [here](#).

The presentation at EANM, which has been selected as a Top Rated Oral Presentation, will be given by Dr Tatjana Gibbons, a key investigator on the study from the Nuffield Department of Women’s and Reproductive Health, University of Oxford. Please see full details here:

Session Date: Sunday, October 20, 2024
Session Time: 9:45:00 AM - 11:15:00 AM
Presentation Number: OP-116
Session Number: 307
Session Title: TROP Session: Paediatrics Committee: Paediatric Nephrourology & Others
Session Hall: Hall Y10-Y12

The study is investigating whether it is possible to visualise endometriosis, including superficial peritoneal disease, using ^{99m}Tc-maraciclalide and SPECT-CT imaging. Superficial peritoneal endometriosis is the most common form of endometriosis accounting for approximately 80% of diagnoses and cannot be reliably detected using existing non-invasive imaging techniques such as ultrasound and MRI. Definitive diagnosis requires laparoscopy and there is an average delay to diagnosis of seven and a half years. This study aims to evaluate the potential of ^{99m}Tc-maraciclalide in detecting endometriosis, and specifically superficial peritoneal endometriosis, which could have a significant impact on the lives of millions of women suffering with the disease.

-ENDS-

Maraciclalide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.

For more information, please contact:

David Hail, Chief Executive Officer

+44 (0)20 8948 0000
info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010820
francettacarr@seraclifesciences.com

Notes to Editors

About Serac Healthcare Ltd

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

www.serachealthcare.com

About the DETECT study

The study is jointly sponsored by Oxford Endometriosis CaRe Centre and the Nuffield Department of Women's and Reproductive Health, Oxford University, and funded by Serac Healthcare Ltd who are providing the experimental imaging marker ^{99m}Tc -maraciclalide. Further details are available on ClinicalTrials.gov [here](#).

About EANM: <https://eanm24.eanm.org/>